These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 18277626

  • 1. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L, Andrýs C, Krejsek J, Belada DZ, Zák P, Siroký O, Malý J.
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [Abstract] [Full Text] [Related]

  • 2. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
    Gora-Tybor J, Blonski JZ, Robak T.
    Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
    [Abstract] [Full Text] [Related]

  • 3. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Jun; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 5. Circulating endothelial cells in patients with chronic lymphocytic leukemia.
    Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, Bottner WA, Cole CE, Farnen JP, Frisby KA.
    Ann Hematol; 2008 May; 87(5):369-73. PubMed ID: 18193423
    [Abstract] [Full Text] [Related]

  • 6. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
    Wróbel T, Poreba M, Mazur G, Poreba R, Pyszel A, Beck B, Steinmetz-Beck A, Andrzejak R, Kuliczkowski K.
    Neoplasma; 2006 May; 53(3):253-8. PubMed ID: 16652197
    [Abstract] [Full Text] [Related]

  • 7. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A.
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [Abstract] [Full Text] [Related]

  • 9. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.
    Gora-Tybor J, Blonski JZ, Robak T.
    Neoplasma; 2002 Dec; 49(3):145-8. PubMed ID: 12097998
    [Abstract] [Full Text] [Related]

  • 10. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G.
    Anticancer Res; 1998 Dec; 18(2A):1123-7. PubMed ID: 9615776
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C.
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.
    Cancer Res; 2001 Mar 15; 61(6):2533-6. PubMed ID: 11289126
    [Abstract] [Full Text] [Related]

  • 16. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
    Bremnes RM, Camps C, Sirera R.
    Lung Cancer; 2006 Feb 15; 51(2):143-58. PubMed ID: 16360975
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
    Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T.
    Eur J Cardiothorac Surg; 2004 Mar 15; 25(3):443-8. PubMed ID: 15019676
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.